Aquestive Therapeutics Inc

NASDAQ:AQSTUnited States

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Contact Information

Headquarters

30 Technology DrWARREN, NJ, United States 07059-5166

Phone

908-941-1900

Fax

302-636-5454

Executives

Independent Chairman of the Board

Santo Costa

President, Chief Executive Officer, Director

Daniel Barber

Independent Vice Chairman of the Board

John Cochran

Chief Financial Officer, Senior Vice President

A. Ernest Toth

Chief Compliance Officer, Senior Vice President, General Counsel and Corporate Secretary

Lori Braender